Apeloa Pharmaceutical Co.,Ltd

Equities

000739

CNE000000Q45

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
14.11 CNY +1.36% Intraday chart for Apeloa Pharmaceutical Co.,Ltd +3.75% -8.32%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apeloa Pharmaceutical Co.,Ltd announces an Equity Buyback for CNY 300 million worth of its shares. CI
Apeloa Pharmaceutical Co.,Ltd authorizes a Buyback Plan. CI
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apeloa Pharmaceutical to Co-Develop Antibody Drug Conjugates With Zhenge Biotechnology MT
Apeloa Pharmaceutical to Scrap Sofadil for Injection Clinical Trial for Stroke MT
Apeloa Pharmaceutical's Profit Climbs 13.6% in Q3 MT
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Apeloa Pharmaceutical to Cooperate With Wuhan Hopson Technology on Customized Production Projects MT
Apeloa Pharma Unit Passes US FDA On-Site Inspection MT
Apeloa Pharmaceutical's Unit Passes US FDA's Inspection MT
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma MT
Apeloa Pharmaceutical to Sell 95% Stake in Injection Unit for 38 Million Yuan MT
Shanxi Heyang Pharmaceutical Ltd entered into an agreement to acquire 95% stake in Shanxi Puheng Pharmaceutical Co., Ltd from Apeloa Pharmaceutical Co.,Ltd for CNY 38 million CI
Apeloa Pharmaceutical Co.,Ltd Approves Election of Pan Weiguang as Independent Director CI
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Apeloa Pharma’s 2022 Profit Rises 3.5% as Revenue Surges 18%; Shares Slide Nearly 6% MT
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Apeloa Pharmaceutical Unit Gets Nod to Manufacture, Supply COVID-19 Drug in China MT
Tranche Update on Apeloa Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on May 5, 2022. CI
Apeloa Pharmaceutical Co.,Ltd's Equity Buyback announced on May 5, 2022, has expired with 9,199,916 shares, representing 0.79% for CNY 200.16 million. CI
Apeloa Pharmaceutical Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tranche Update on Apeloa Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on May 5, 2022. CI
Apeloa Pharma’s Arrhythmia Treatment Secures Drug Registration Certificate in China MT
Chart Apeloa Pharmaceutical Co.,Ltd
More charts
Apeloa Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredient (API) intermediates, contract development and manufacturing organization (CDMO), preparations and others, as well as import and export trade. The Company operates three businesses. The API intermediates business mainly includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary API intermediates series. The CDMO business mainly includes research and development services, commercial human drug projects, commercial veterinary drug projects and other commercial products. The preparation business mainly includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor preparation products. The Company mainly operates its businesses in domestic and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
14.11 CNY
Average target price
17.75 CNY
Spread / Average Target
+25.80%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000739 Stock
  4. News Apeloa Pharmaceutical Co.,Ltd
  5. Apeloa Pharma Unit Passes US FDA On-Site Inspection